PLUS THERAPEUTICS, INC. — fact timeline

PLUS THERAPEUTICS, INC. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at $17,350,000 (effective 2026-06-01).

“On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent acting as an agent for sales.”

PLUS THERAPEUTICS, INC. shareholders approved Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan at the 2026-05-14 meeting.

“Proposal No. 4 – Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan. The Company’s stockholders approved the sixth amendment and restatement of the Company’s 2020 Stock Incentive Plan. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,976,002 5,648,887 425,414 50,807,018”

PLUS THERAPEUTICS, INC. shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-05-14 meeting.

“Proposal No. 3 - Advisory Vote on the Compensation of Named Executive Officers. The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,389,498 3,364,694 296,111 50,807,018”

PLUS THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.

“Proposal No. 2 - Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of CBIZ CPAs, P.C. as the Company’s independent registered public accounting firm for the 2026 fiscal year. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 60,860,051 2,292,062 1,705,208 0”

PLUS THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-05-14 meeting.

“Proposal No. 1 - Election of Directors. The Company's stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for a term expiring at the Company’s Annual Meeting of Stockholders in 2027 and until each such person’s successors is duly elected and qualified, or until his or her earlier death, resignation or removal: Votes For Votes Withheld Broker Non-Votes Howard Clowes 11,863,579 2,186,724 50,807,018 An van Es-Johansson, M.D. 12,384,866 1,665,437 50,807,018 Richard J. Hawkins 12,344,152 1,706,151 50,807,018 Marc H. Hedrick, M.D. 12,350,511 1,699,792 50,807,018 Ronald A. Andrews 12,417,138 1,633,165 50,807,018 Kyle Guse, Esq., MBA, CPA 12,384,591 1,665,712 50,807,018”

PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $1.0 million, net income $6.9 million, or $1.05 per basic share, EPS $1.05 per basic share. Guidance reaffirmed.

“2026 public offering, partially offset by operating expenditures during the quarter and paydown of the investor liability at December 31, 2025 of $4.5 million • Recognized $1.0 million in revenue in the first quarter of 2026, including grant revenue from CPRIT for the advancement of REYOBIQ in LM and CNSide diagnostic billings, compared to $1.1 million in the”

PLUS THERAPEUTICS, INC.: Amendment to Certificate of Incorporation to effect a 1-for-25 reverse stock split of common stock, approved by stockholders and Board, effective April 2, 2026 (effective 2026-04-02).

“the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-25 reverse split of its common stock (the “Reverse Stock Split”).”

PLUS THERAPEUTICS, INC. entered into Underwriting Agreement with Lake Street Capital Markets, LLC valued at combined public offering price of $0.38 per share and Warrant (effective 2026-01-13).

“On January 13, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as the underwriter (the “Underwriter”), pursuant to which the Company (a) agreed to issue and sell, in an underwritten public offering (the “Offering”), an aggregate of (i) 39,473,684 shares of common stock, par value $ 0.001 per share (the “Common Stock”), of the Company and (ii) warrants to purchase 39,473,684 shares of Common Stock (the “Warrants”), at a combined public offering price of $0.38 per share and Warrant”

PLUS THERAPEUTICS, INC. engaged CBIZ CPAs P.C. as its auditor.

“The Audit Committee discussed this matter with BDO, and the Company has authorized BDO to respond fully to any inquiries of CBIZ CPAs P.C. (“CBIZ”) with respect to this matter. The Company provided BDO with a copy of this current report on Form 8-K (the “ Form 8-K ”) prior to its filing with the U.S. Securities and Exchange Commission (the “ SEC ”) and requested that BDO furnish the Company with a letter addressed to the SEC stating whether BDO agrees with the statements made by the Company in this Form 8-K and, if not, stating the respects, if any, in which BDO does not agree with such statements. A copy of the letter from BDO is filed with this Form 8-K as Exhibit 16.1. (b) Engagement of New Independent Registered Public Accounting Firm On July 16, 2025, the Audit Committee approved the engagement of CBIZ effective immediately as the Company’s new independent registered public accounti”

PLUS THERAPEUTICS, INC. dismissed BDO USA, P.C. as its auditor.

“(a) Dismissal of Independent Registered Public Accounting Firm On July 16, 2025, the audit committee (the “ Audit Committee ”) of the board of directors of Plus Therapeutics, Inc. (the “ Company ”) dismissed BDO USA, P.C. (“ BDO ”) as the Company’s independent registered public accounting firm.”

PLUS THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“June 3, 2025, Plus Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the Rule 5250(c)(1) due to filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”) on May 30, 2025. As previously disclosed, on March 8, 2024, the Company received a written notice from the Staff, notifying the Company that it no longer complied with the requir”

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 21, 2025, Plus Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Notice states that the Company has until July 21, 2025, to su”

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 16, 2025, Plus Therapeutics, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Nasdaq’s notice has no immediate effect on the listing or trading of the Company’s common stock. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided an initial compliance period of 180 ca”

PLUS THERAPEUTICS, INC.: Increased authorized shares of common stock from 100,000,000 to 2,000,000,000 (effective 2025-05-02).

“the stockholders of the Company approved a Certificate of Amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the authorized shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from 100,000,000 shares to 2,000,000,000 shares”

Greg Petersen resigned as Director at PLUS THERAPEUTICS, INC..

“On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”

Kyle Guse was appointed as Director at PLUS THERAPEUTICS, INC..

“On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.”

PLUS THERAPEUTICS, INC. incurred convertible notes of $3,362,251 with certain existing accredited investors at 10% per annum maturing February 13, 2026.

“On February 13, 2025 (the “Closing Date”), Plus Therapeutics, Inc. (the “Company”) entered into a Securities Purchase and Exchange Agreement (the “SPEA”) with certain existing accredited investors (the “Purchasers”). Pursuant to the SPEA, on the Closing Date the Company issued secured convertible promissory notes (the “Funding Notes”) in the aggregate principal amount of $3,362,251 together with common stock purchase warrants (the “Warrants”) to purchase 3,002,009 shares of the Company common stock, par value $0.001 (the “Common Stock”) at an exercise price of $1.12 per share (the “Warrant Exercise Price”).”

Dr. Norman LaFrance resigned as Chief Medical Officer at PLUS THERAPEUTICS, INC..

“On June 5, 2024, Plus Therapeutics, Inc. (the “Company”) received the resignation of Dr. Norman LaFrance, its Chief Medical Officer.”

PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $1.7 million in grant revenue, net income $3.3 million, EPS $(0.75) per share.

“FIRST QUARTER 2024 FINANCIAL RESULTS • The Company’s cash balance was $3 million at March 31, 2024 compared to $8.6 million at December 31, 2023. • The Company recognized $1.7 million in grant revenue in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023, which represents CPRIT’s share of the costs incurred for the Company’s rhenium ( 186 Re) obisbemeda development for the treatment of patients with LM • Total operating loss for the first quarter of 2024 was $3.3 million compared to $4.8 million in the same period of 2023. The decrease was primarily due to increased grant revenue • Net loss for first quarter of 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year”

PLUS THERAPEUTICS, INC. amended Securities Purchase Agreement with certain investors identified on the signature page thereto (collectively, the "Purchasers") valued at approximately $0.75 million (effective 2024-05-08).

“On May 8, 2024, the Company entered into an amendment to the Securities Purchase Agreement (the “Amendment”) that increased the aggregate subscription amount by approximately $0.75 million (the “Additional Subscription”) for aggregate initial gross proceeds of approximately $7.25 million.”

PLUS THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain investors identified on the signature page thereto (collectively, the "Purchasers") valued at approximately $6.5 million (effective 2024-05-05).

“On May 5, 2024, Plus Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors identified on the signature page thereto (collectively, the “Purchasers”) for a private placement of securities (the “Initial Subscription”) for gross proceeds at the Closing Date (as defined below) of approximately $6.5 million.”

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 8, 2024, Plus Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or”

PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income $(13.3) million, or $(4.24) per share, EPS $(4.24) per share.

“Plus Therapeutics, Inc. (the “Company”) reported financial results for the fourth quarter and year ended December 31, 2023”

PLUS THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: net income $(3.2) million, or $(1.00) per share, EPS $(1.00) per share.

“Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights”

PLUS THERAPEUTICS, INC. reported the second quarter ended June 30, 2023 results: net income $(1.5) million, EPS $(0.59) per share.

“Net loss for the second quarter of 2023 was $(1.5) million, or $(0.59) per share”

PLUS THERAPEUTICS, INC.: Amendment to the Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of common stock (effective 2023-05-01).

“On April 27, 2023, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-15 reverse split of its common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective as of 12:01 a.m. (Eastern time) on May 1, 2023, and the Company’s common stock will begin trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023.”

PLUS THERAPEUTICS, INC. shareholders approved Approval of the third amendment and restatement of the Company’s 2020 Stock Incentive Plan at the 2023-04-20 meeting.

“6. Proposal to approve the third amendment and restatement of the Company’s 2020 Stock Incentive Plan: For Against Abstain 4,279,475 2,112,637 103,766”

PLUS THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a ratio of not less than 1-for-3 and not greater than 1-for-15 at the 2023-04-20 meeting.

“5. Proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-fifteen (1:15): For Against Abstain 52,798,957 12,179,757 517,698”

PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation at the 2023-04-20 meeting.

“4. Proposal to provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation: One Year Two Years Three Years Abstain 5,695,824 105,972 401,874 292,208”

PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2023-04-20 meeting.

“3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers: For Against Abstain 4,580,421 1,735,989 179,468”

PLUS THERAPEUTICS, INC. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year at the 2023-04-20 meeting.

“2. Proposal to ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year: For Against Abstain 14,681,590 617,972 196,849”

PLUS THERAPEUTICS, INC. shareholders approved Election of six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified at the 2023-04-20 meeting.

“1. Proposal to elect six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified: For Withheld Broker Non-Votes Howard Clowes 5,306,629 1,189,249 9,000,533 An van Es-Johansson 5,387,484 1,108,394 9,000,533 Richard J. Hawkins 5,364,397 1,131,481 9,000,533 Marc H. Hedrick, M.D. 5,700,185 795,693 9,000,533 Robert Lenk 5,308,285 1,187,593 9,000,533 Greg Petersen 5,675,200 820,678 9,000,533”

PLUS THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue $506,000, net income $4.8 million, EPS $(0.14) per share.

“FIRST QUARTER 2023 FINANCIAL RESULTS ▪ The Company’s cash balance was $12.7 million at March 31, 2023, compared to $18.1 million at December 31, 2022. ▪ The Company recognized $506,000 of grant revenue in the first quarter of 2023, which represents the Cancer Prevention & Research Institute of Texas’ (CPRIT) share of costs incurred in the development of rhenium”

PLUS THERAPEUTICS, INC.: Filed a certificate of designation for Preferred Stock with specific voting rights and redemption provisions (effective 2023-03-03).

“On March 3, 2023, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Preferred Stock.”

PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2022 results: net income $20.3 million, EPS $(0.77) per share.

“Net loss for full year 2022 was $20.3 million, or $(0.77) per share, compared to a net loss of $13.4 million, or $(1.11) per share, for full year 2021.”

PLUS THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 22, 2022, the Company received a second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock”

Norman LaFrance was appointed as Chief Medical Officer at PLUS THERAPEUTICS, INC..

“On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.”